mhurhangee/ep-ind-claims huggingface dataset:
A method for producing a needle cannula comprising: (i.) providing a needle cannula tube, wherein the needle cannula tube comprises an end portion comprising: - an outer surface, - and a steel alloy, (ii.) providing an electrolyte, and (iii.) bringing the end portion into contact with the electrolyte, (iv.) applying a potential between the needle cannula tube and a cathode, and thereby establishing an electrochemical reaction to remove material from the outer surface of the end portion, and thereby providing a needle cannula with a tapered end portion, characterized in that the steel alloy comprises carbon in 0.07 to 0.15 % by mass, silicon (Si) in 0.50 to 1.00 % by mass, manganese (Mn) in 5.0 to 7.5 % by mass, phosphorus in 0 to 0.030 % by mass, sulfur in less than or equal to 0.015 % by mass, chromium (Cr) in 17.5 to 19.5 % by mass, nickel (Ni) in 6.5 to 8.5 % by mass, and nitrogen in 0.20 to 0.30 % by mass. (i.) providing a needle cannula tube, wherein the needle cannula tube comprises an end portion comprising: - an outer surface, - and a steel alloy, - an outer surface, - and a steel alloy, (ii.) providing an electrolyte, and (iii.) bringing the end portion into contact with the electrolyte, (iv.) applying a potential between the needle cannula tube and a cathode, and thereby establishing an electrochemical reaction to remove material from the outer surface of the end portion, and thereby providing a needle cannula with a tapered end portion, characterized in that the steel alloy comprises carbon in 0.07 to 0.15 % by mass, silicon (Si) in 0.50 to 1.00 % by mass, manganese (Mn) in 5.0 to 7.5 % by mass, phosphorus in 0 to 0.030 % by mass, sulfur in less than or equal to 0.015 % by mass, chromium (Cr) in 17.5 to 19.5 % by mass, nickel (Ni) in 6.5 to 8.5 % by mass, and nitrogen in 0.20 to 0.30 % by mass.
An antisense oligonucleotide, capable of inhibiting the expression of human PCSK9, wherein said antisense oligonucleotide is 10-25 nucleobases in length and is complementary to a corresponding region of SEQ ID NO 2; wherein the antisense oligonucleotide is a gapmer oligonucleotide of formula A-B-C, wherein; A consists or comprises of 1-6 nucleotide analogues and; B consists or comprises between 4-12 consecutive DNA nucleobases, and; C consists or comprises of 1-6 nucleotide analogues; wherein the nucleotide analogues of A and C raise the T m of the oligonucleotide/target duplex. A consists or comprises of 1-6 nucleotide analogues and; B consists or comprises between 4-12 consecutive DNA nucleobases, and; C consists or comprises of 1-6 nucleotide analogues; wherein the nucleotide analogues of A and C raise the T m of the oligonucleotide/target duplex.
A welding machine for welding free ends of bar conductors of a stator of an electrical machine, in particular an electric motor, comprising: - a support structure for directly or indirectly fixing the stator, having a welding mask which can be opened and closed; - a welding device, in particular a laser welding device, wherein the welding device is arranged above the support structure, and wherein the support structure can be moved between a welding position and a loading position, wherein a first side of the welding mask is oriented towards the welding device in the welding position and is oriented downward in the loading position. - a support structure for directly or indirectly fixing the stator, having a welding mask which can be opened and closed; - a welding device, in particular a laser welding device, wherein the welding device is arranged above the support structure, and wherein the support structure can be moved between a welding position and a loading position, wherein a first side of the welding mask is oriented towards the welding device in the welding position and is oriented downward in the loading position.
A process for treating a waste anesthetic gas containing a volatile anesthetic and nitrous oxide discharged from an operating room comprising steps of contacting the gas with an adsorbent, thereby adsorption-removing the volatile anesthetic contained in the waste anesthetic gas, and then contacting the gas containing nitrous oxide with a catalyst for decomposing the nitrous oxide, thereby decomposing the nitrous oxide, wherein the temperature at the decomposition of the nitrous oxide is from 200 to 600 °C, wherein the catalyst for decomposing the nitrous oxide is an alumina-type catalyst, at least one catalyst selected from the group consisting of the following catalysts to: a catalyst comprising a support having supported thereon aluminum, magnesium and rhodium, a catalyst comprising an alumina support having supported thereon magnesium and rhodium, and a catalyst comprising a support having supported thereon rhodium, the support having therein a spinel crystalline complex oxide formed by magnesium and at least a part of aluminum, or at least one catalyst selected from the group consisting of the following catalysts to: a catalyst comprising a support having supported thereon aluminum, rhodium and at least one metal selected from the group of zinc, iron and manganese, a catalyst comprising an alumina support having supported thereon rhodium and at least one metal selected from the group of zinc, iron and manganese, and a catalyst comprising a support having supported thereon rhodium, the support having therein a spinel crystalline complex oxide formed by at least a part of aluminum and at least one mental selected from the group of zinc, iron and manganese, wherein the concentration of the nitrous oxide contained after the decomposition of the nitrous oxide is detected and the temperature at the decomposition of the nitrous oxide is controlled based on the detected concentration of nitrous oxide. a catalyst comprising a support having supported thereon aluminum, magnesium and rhodium, a catalyst comprising an alumina support having supported thereon magnesium and rhodium, and a catalyst comprising a support having supported thereon rhodium, the support having therein a spinel crystalline complex oxide formed by magnesium and at least a part of aluminum, or at least one catalyst selected from the group consisting of the following catalysts to: a catalyst comprising a support having supported thereon aluminum, rhodium and at least one metal selected from the group of zinc, iron and manganese, a catalyst comprising an alumina support having supported thereon rhodium and at least one metal selected from the group of zinc, iron and manganese, and a catalyst comprising a support having supported thereon rhodium, the support having therein a spinel crystalline complex oxide formed by at least a part of aluminum and at least one mental selected from the group of zinc, iron and manganese,
A computer program comprising instructions that, when executed by one or more processing devices, cause the one or more processing devices to perform a method of automatically generating an integrated model that integrates a plurality of predictive models, the integrated model operable to select one or more predictive models based on patient data, and suitable for planning a radiation therapy, said method comprising: configuring an input interface operable to receive patient data pertaining to radiation therapy, the patient data comprising a plurality of features comprising parameters that practically affect the therapy accessing the plurality of predictive models, wherein each predictive model is operable to generate a therapy prediction based on said patient data (101, 401, 501); integrating in the integrated model said plurality of predictive models into a hierarchy comprising a bottom level and a plurality of decision levels (A, B, C), each decision level (A, B, C) corresponding to a respective feature set (F1, F2, F3) in the patient data and each feature set (F1, F2, F3) corresponding to one or more features in the patient data, and wherein each decision level (A, B, C) includes multiple predefined categories of a respective feature set (F1, F2, F3); wherein said bottom level comprises said plurality of predictive models, and wherein said plurality of decision levels (A, B, C) are operable to automatically select one or more predictive models from said bottom level based on said categories associated with said decision levels (A, B, C); and configuring an output interface operable to output a therapy prediction generated by an automatically selected predictive model in response to said patient data. configuring an input interface operable to receive patient data pertaining to radiation therapy, the patient data comprising a plurality of features comprising parameters that practically affect the therapy accessing the plurality of predictive models, wherein each predictive model is operable to generate a therapy prediction based on said patient data (101, 401, 501); integrating in the integrated model said plurality of predictive models into a hierarchy comprising a bottom level and a plurality of decision levels (A, B, C), each decision level (A, B, C) corresponding to a respective feature set (F1, F2, F3) in the patient data and each feature set (F1, F2, F3) corresponding to one or more features in the patient data, and wherein each decision level (A, B, C) includes multiple predefined categories of a respective feature set (F1, F2, F3); wherein said bottom level comprises said plurality of predictive models, and wherein said plurality of decision levels (A, B, C) are operable to automatically select one or more predictive models from said bottom level based on said categories associated with said decision levels (A, B, C); and configuring an output interface operable to output a therapy prediction generated by an automatically selected predictive model in response to said patient data.
Apparatus for generating an error concealment audio signal, comprising: a linear predictive coding, LPC, representation generator for generating a first replacement LPC representation and a different second replacement LPC representation; an LPC synthesizer for filtering a first codebook information using the first LPC replacement representation to obtain a first replacement signal and for filtering a different second codebook information using the second replacement LPC representation to obtain a second replacement signal; and a replacement signal combiner for combining the first replacement signal and the second replacement signal by summing-up the first replacement signal and the second replacement signal to obtain the error concealment audio signal. a linear predictive coding, LPC, representation generator for generating a first replacement LPC representation and a different second replacement LPC representation; an LPC synthesizer for filtering a first codebook information using the first LPC replacement representation to obtain a first replacement signal and for filtering a different second codebook information using the second replacement LPC representation to obtain a second replacement signal; and a replacement signal combiner for combining the first replacement signal and the second replacement signal by summing-up the first replacement signal and the second replacement signal to obtain the error concealment audio signal.
Ocular iontophoresis device for drug delivery, this device comprising: a drug reservoir configured so as to store a drug in solution, this reservoir being able to be positioned on the eye, an active electrode disposed in the reservoir, characterised in that this active electrode contains an electrically conductive layer arranged so as to receive an electric field capable of polarising it sufficiently to electrolyse the drug when it is stored in the reservoir, in a solution having a pH situated in the range of approximately 4.5 to approximately 11.5, and a passive electrode, and in which the drug is transported effectively through at least either the cornea or the sclera of the eye due to the iontophoresis induced by the active and passive electrodes. a drug reservoir configured so as to store a drug in solution, this reservoir being able to be positioned on the eye, an active electrode disposed in the reservoir, characterised in that this active electrode contains an electrically conductive layer arranged so as to receive an electric field capable of polarising it sufficiently to electrolyse the drug when it is stored in the reservoir, in a solution having a pH situated in the range of approximately 4.5 to approximately 11.5, and a passive electrode, and in which the drug is transported effectively through at least either the cornea or the sclera of the eye due to the iontophoresis induced by the active and passive electrodes.
A distributed base station, comprising a Baseband Unit, BBU, and a power system and at least two radio remote units, RRUs, wherein the two RRUs comprise a first RRU and a second RRU; and further comprising a power supply apparatus, wherein a first input end of the direct current output unit of the power supply apparatus is connected an output end of the power system, a second output end of the direct current output unit of the power supply apparatus is connected to an input end of the first RRU and the second RRU, and the power supply apparatus is configured to receive power output by the power system and provide the power for the first RRU and the second RRU, wherein a length of a direct current power cable between the first RRU and the power supply apparatus is less than a length of a direct current power cable between the first RRU and the power system, and a length of a direct current power cable between the second RRU and the power supply apparatus is less than a length of a direct current power cable between the second RRU and the power system, characterized in that the first RRU, the second RRU, and the power supply apparatus are all disposed on a first tower; further comprising: a second tower, wherein a third RRU is disposed on the second tower, the second output end of the direct current output unit of the power supply apparatus is also connected to an input end of the third RRU, and the power supply apparatus is configured to provide power for the third RRU, wherein a length of a direct current power cable between the third RRU and the power supply apparatus is less than a length of a direct current power cable between the third RRU and the power system. a second tower, wherein a third RRU is disposed on the second tower, the second output end of the direct current output unit of the power supply apparatus is also connected to an input end of the third RRU, and the power supply apparatus is configured to provide power for the third RRU, wherein a length of a direct current power cable between the third RRU and the power supply apparatus is less than a length of a direct current power cable between the third RRU and the power system.
Cleaning device, in particular a floor cleaning device or above-floor cleaning device, comprising a cleaning roller that is rotatable about an axis of rotation, a motor that drives the cleaning roller, and a device gearing-mechanism which is arranged between the cleaning roller and the motor, characterised in that the cleaning device also comprises a device interface for connecting the cleaning roller to the motor in a power-transmitting manner via an external gearing mechanism, in particular a base-station gearing mechanism of a base station, the device interface comprising a first device interface element, in particular a gearwheel, and a second device interface element, in particular a gear wheel.
An overlay for placement on the back of a mount, comprising - at least one base body and - a plurality of contact elements, wherein the base body can be adjusted to the anatomy of the back of the mount, and at least partially covers the back of the mount, wherein the contact elements are arranged on an underside of the base body, so that the contact elements can be brought into contact with the back of the mount, wherein the contact elements each protrude at least partially over a base area of the underside of the base body, characterized in that at least one respective group of contact elements spaced apart from each other and running parallel to each other are arranged on both sides of a center axis of the base body, wherein the contact elements are each stitched with the base body along at least one connecting line, wherein the width of the contact elements measured parallel to the base area of the overlay measures between 10 mm and 30 mm, preferably between 15 mm and 25 mm. - at least one base body and - a plurality of contact elements, wherein the base body can be adjusted to the anatomy of the back of the mount, and at least partially covers the back of the mount, wherein the contact elements are arranged on an underside of the base body, so that the contact elements can be brought into contact with the back of the mount, wherein the contact elements each protrude at least partially over a base area of the underside of the base body, characterized in that at least one respective group of contact elements spaced apart from each other and running parallel to each other are arranged on both sides of a center axis of the base body, wherein the contact elements are each stitched with the base body along at least one connecting line, wherein the width of the contact elements measured parallel to the base area of the overlay measures between 10 mm and 30 mm, preferably between 15 mm and 25 mm.
A method of producing INS+ NKX6.1+ immature β-like cells from human pluripotent stem cells comprising: (a) incubating pluripotent stem cells (PSCs) in culture medium comprising Wnt3a, Activin A, an inhibitor of TGFβ, and keratinocyte growth factor for 3-7 days; (b) exposing the cells resulting from step (a) to medium comprising retinoic acid for 2-3 days; (c) culturing the cells resulting from step (b) in medium comprising RA, epidermal growth factor, and KGF, thereby producing a culture comprising greater than 70% PDX1 + NKX6.1 + endocrine progenitor cells; and (d) incubating the culture comprising PDX1 + NKX6.1 + endocrine progenitor cells in medium comprising ALK5 inhibitor (Alki), T3, XXi, LDN-193189, non-essential amino acids (NEAA), N -acetyl Cysteine, zinc sulfate, glutamax, heparin, and vitamin C for at least 8 days, thereby producing INS + NKX6.1 + immature β-like cells, preferably the culture is incubated for 8-10 days. (a) incubating pluripotent stem cells (PSCs) in culture medium comprising Wnt3a, Activin A, an inhibitor of TGFβ, and keratinocyte growth factor for 3-7 days; (b) exposing the cells resulting from step (a) to medium comprising retinoic acid for 2-3 days; (c) culturing the cells resulting from step (b) in medium comprising RA, epidermal growth factor, and KGF, thereby producing a culture comprising greater than 70% PDX1 + NKX6.1 + endocrine progenitor cells; and (d) incubating the culture comprising PDX1 + NKX6.1 + endocrine progenitor cells in medium comprising ALK5 inhibitor (Alki), T3, XXi, LDN-193189, non-essential amino acids (NEAA), N -acetyl Cysteine, zinc sulfate, glutamax, heparin, and vitamin C for at least 8 days, thereby producing INS + NKX6.1 + immature β-like cells, preferably the culture is incubated for 8-10 days.
An infrared reflecting fiber, characterized by being fabricated by a method comprising: mixing 76.0 parts by weight to 88.5 parts by weight of a carrier, 1.8 parts by weight to 4.0 parts by weight of an infrared reflecting composition, 2.5 parts by weight to 7.5 parts by weight of a titanium dioxide containing composition, and 6.0 parts by weight to 16.0 parts by weight of a color adjusting composition, wherein the carrier comprises polyethylene terephthalate, wherein the infrared reflecting composition comprises an infrared reflecting colorant comprising a black infrared reflecting colorant, a yellow infrared reflecting colorant, or combinations thereof, the color adjusting composition comprises a color adjusting colorant comprising a yellow color adjusting colorant, a red color adjusting colorant, a blue color adjusting colorant, a green color adjusting colorant, a purple color adjusting colorant, or combinations thereof, and when a content of 5.0 wt% to 7.5 wt% of the infrared reflecting composition and a balance of the carrier are mixed together to form a first fiber, a maximum infrared reflectivity of the first fiber is between 61% and 70%.
A process transmitter comprising: an isolation unit configured to engage a process and including a medium; a process sensor configured to produce a process signal that is a function of a parameter of the process that is communicated through the medium; a compensation circuit configured to compensate the process signal for a response time of the isolation unit, and output a compensated process signal, wherein the compensation is a function of a hydraulic impedance of the medium; and an output circuit configured to receive the compensated process signal and produce a transmitter output as a function of the compensated process signal. an isolation unit configured to engage a process and including a medium; a process sensor configured to produce a process signal that is a function of a parameter of the process that is communicated through the medium; a compensation circuit configured to compensate the process signal for a response time of the isolation unit, and output a compensated process signal, wherein the compensation is a function of a hydraulic impedance of the medium; and an output circuit configured to receive the compensated process signal and produce a transmitter output as a function of the compensated process signal.